Scoop: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout
Celgene has completed a deal to acquire the Swiss biotech EngMab for $600 million, adding a new BCMA-targeting multiple myeloma program to the pipeline, Endpoints News has learned. And it’s putting the new tech to work with its ongoing efforts on CAR-T and CD-3 antibodies with an eye on finding a cure for myeloma and lymphoma.
A Celgene spokesperson confirmed the deal to me in a statement Friday morning, saying that “we are acquiring Engmab for $600 million.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters